Detailed view for LmjF.21.1010

Basic information

TDR Targets ID: 28024
Leishmania major, epsilon tubulin, putative

Source Database / ID:  TriTrypDB  GeneDB

pI: 6.3534 | Length (AA): 470 | MW (Da): 51793 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Pfam domains

PF00091   Tubulin/FtsZ family, GTPase domain
PF03953   Tubulin C-terminal domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0043234   protein complex  
GO:0005874   microtubule  
GO:0003924   GTPase activity  
GO:0005525   GTP binding  
GO:0005198   structural molecule activity  
GO:0051258   protein polymerization  
GO:0007018   microtubule-based movement  
GO:0007017   microtubule-based process  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 7 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
2 453 1z5v (A) 2 440 30.00 0 1 1.28 -1.09
3 453 2bto (A) 4 432 28.00 0 1 1.26 -1.44
3 454 1sa0 (B) 2 438 32.00 0 1 1.35 -1.1
2 462 3cb2 (A) 2 446 28.00 0 1 1.24865 -0.49
3 457 4i4t (D) 2 441 31.00 0 1 1.34589 -0.79
3 448 1ffx (B) 2 432 34.00 0 1 1.21894 0.23
3 459 2btq (A) 4 439 28.00 0 1 1.29334 -0.89

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile amastigotes. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile metacyclic. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_130726)

Species Accession Gene Product
Echinococcus granulosus EgrG_000603100   tubulin epsilon chain
Echinococcus multilocularis EmuJ_000603100   tubulin epsilon chain
Giardia lamblia GL50803_6336   Epsilon tubulin
Homo sapiens ENSG00000074935   tubulin, epsilon 1
Leishmania braziliensis LbrM.21.1240   epsilon tubulin, putative
Leishmania donovani LdBPK_211250.1   epsilon tubulin, putative
Leishmania infantum LinJ.21.1250   epsilon tubulin, putative
Leishmania major LmjF.21.1010 this record   epsilon tubulin, putative
Leishmania mexicana LmxM.21.1010   epsilon tubulin, putative
Mus musculus ENSMUSG00000019845   epsilon-tubulin 1
Neospora caninum NCLIV_007070   tubulin epsilon chain, putative
Plasmodium berghei PBANKA_1300500   tubulin epsilon chain, putative
Plasmodium falciparum PF3D7_1475700   tubulin epsilon chain, putative
Plasmodium knowlesi PKNH_1246000   tubulin epsilon chain, putative
Plasmodium vivax PVX_118660   tubulin epsilon chain, putative
Plasmodium yoelii PY05777   tubulin beta chain
Schistosoma japonicum Sjp_0009290   ko:K10391 tubulin epsilon, putative
Schistosoma mansoni Smp_028360   tubulin subunit epsilon
Schmidtea mediterranea mk4.013167.01   Tubulin epsilon chain
Schmidtea mediterranea mk4.013167.02   Tubulin epsilon chain, putative
Schmidtea mediterranea mk4.016956.01   Tubulin epsilon chain, putative
Schmidtea mediterranea mk4.023212.00   Tubulin epsilon chain, putative
Schmidtea mediterranea mk4.016956.00  
Trypanosoma brucei gambiense Tbg972.10.1240   epsilon tubulin
Trypanosoma brucei Tb927.10.1140   epsilon tubulin
Trypanosoma brucei Tb11.0530   epsilon tubulin
Trypanosoma congolense TcIL3000_10_940   epsilon tubulin
Trypanosoma cruzi TcCLB.509967.160   epsilon tubulin, putative
Trypanosoma cruzi TcCLB.509695.120   epsilon tubulin, putative
Toxoplasma gondii TGME49_275970   tubulin, putative
Toxoplasma gondii TGME49_275870   tubulin/FtsZ family, GTPase domain-containing protein
Trichomonas vaginalis TVAG_065740   tubulin gamma chain, putative

Essentiality

LmjF.21.1010 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb927.10.1140 Trypanosoma brucei significant gain of fitness in bloodstream forms (3 days) alsford
Tb927.10.1140 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (6 days) alsford
Tb927.10.1140 Trypanosoma brucei no significant loss or gain of fitness in procyclic forms alsford
Tb927.10.1140 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
PBANKA_1300500 Plasmodium berghei Dispensable plasmo
TGME49_275870 Toxoplasma gondii Probably non-essential sidik
TGME49_275970 Toxoplasma gondii Probably non-essential sidik
Show/Hide essentiality data references
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan

Phenotypes and Validation (curated)

Annotated phenotypes:

Affected Entity Phenotypic quality Occurs in Occurs at Evidence Observed in Drugs/Inhibitors
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania amazonensis No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 09/08/82. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; . References: 2392684
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania amazonensis No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 09/08/82. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; . References: 2392684
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 79195  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 2044859
morphology (PATO:0000051) abnormal (PATO:0000460) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from visible phenotype (ECO:0000176) Leishmania mexicana 79195  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 2044859
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana 79195  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 2044859
cell differentiation (GO:0030154) disrupted (PATO:0001507) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 79195  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with antimicrotubule agents leads to disrupted differentiation from promastigote to amastigote of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 2044859
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania amazonensis 586034  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 95480-32-3. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 8468004
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania amazonensis 13316   39854   79195   544264   551075   552236   554547   555991   557331   559236   559237   559604   561797   562909   564379   564831   568817   568820   568821   569525  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 29091-21-2. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 7818612
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania major 39854   250338   536202  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 121-50-6; Drug: 394-25-2; Drug: 14371-82-5; Drug: 22227-59-4; Drug: 174824-16-9; Drug: 176177-41-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 8849257
microtubule polymerization (GO:0046785) decreased (PATO:0000468) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from specific protein inhibition (ECO:0000020) Leishmania amazonensis 2976   8265   27599   67873   86876   250338   327961   371083   376038   543486   543487   559148   560712   572272   575226   588233  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 16037-91-5. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin and in live cells; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 10029309
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania amazonensis 2976   8265   27599   67873   86876   250338   327961   371083   376038   543486   543487   559148   560712   572272   575226   588233  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 16037-91-5. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 10029309
microtubule polymerization (GO:0046785) increased (PATO:0000470) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 2976   8265   559148  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with microtubule stabilising agent forces mictotubule formation in live cells and interrupts cell cycle; unclear as to which topoisomerase II gene/enzyme was studied. References: 10427726
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 2976   8265   559148  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with microtubule stabilising agent forces mictotubule formation in live cells and interrupts cell cycle; unclear as to which topoisomerase II gene/enzyme was studied. References: 10427726
growth (GO:0040007) drug insensitive (PATO:0000528) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 2976   8265   559148  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with microtubule stabilising agent generated cell line resistant to drug with a MDR phenotype; reversible with Ca2+-channel blocker verapamil; unclear as to which topoisomerase II gene/enzyme was studied. References: 10427727
growth (GO:0040007) drug insensitive (PATO:0000528) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania infantum 37094   39854   79195   250338   551075   562909  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 10546848
microtubule polymerization (GO:0046785) decreased (PATO:0000468) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 11071278
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 11071278
cytokinesis (GO:0000910) discontinuous (PATO:0000690) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from visible phenotype (ECO:0000176) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 11071278
mitotic sister chromatid segregation (GO:0000070) discontinuous (PATO:0000690) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from visible phenotype (ECO:0000176) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 11071278
organelle localization (GO:0051640) discontinuous (PATO:0000690) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from visible phenotype (ECO:0000176) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 11071278
morphology (PATO:0000051) abnormal (PATO:0000460) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from visible phenotype (ECO:0000176) Leishmania donovani 2976   8265   80107   559148   576689   576690  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 11071278
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 12596   13316   15907   26907   78691   79195   527824   528258   531885   531886   532164   532165   532166   532195   532196   532197   532198   532199   532642   532643   532644   536969   536970   544264   552236   554547   559604   561797   564379   568817   568820   568821  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 12161141
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani 12596   13316   15907   26907   78691   79195   527824   528258   531885   531886   532164   532165   532166   532195   532196   532197   532198   532199   532642   532643   532644   536969   536970   544264   552236   554547   559604   561797   564379   568817   568820   568821  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 12161141
microtubule polymerization (GO:0046785) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 12596   13316   15907   26907   78691   79195   527824   528258   531885   531886   532164   532165   532166   532195   532196   532197   532198   532199   532642   532643   532644   536969   536970   544264   552236   554547   559604   561797   564379   568817   568820   568821  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase II gene/enzyme was studied. References: 12161141
cell cycle arrest (GO:0007050) abnormal (PATO:0000460) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 79195  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 483279-40-9; Drug: 483279-44-3. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. References: 14645662
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani 79195  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 19044-89-4; Drug: 19044-94-1; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 619267-13-9; Drug: 619267-14-0; Drug: 619267-15-1; Drug: 619267-16-2; Drug: 619267-17-3; Drug: 619267-18-4; Drug: 619267-19-5; Drug: 619267-20-8; Drug: 619267-21-9; Drug: 619267-22-0; Drug: 619267-23-1; Drug: 619267-24-2; Drug: 619267-25-3; Drug: 619267-26-4; Drug: 678187-02-5; Drug: 678187-03-6; Drug: 678187-04-7; Drug: 678187-05-8; Drug: 678187-06-9; Drug: 678187-07-0; Drug: 678187-08-1; Drug: 678187-09-2; Drug: 678187-10-5; Drug: 678187-11-6; Drug: 678187-12-7; Drug: 678187-13-8; Drug: 678187-14-9. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 15027874
microtubule polymerization (GO:0046785) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 79195  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 19044-89-4; Drug: 19044-94-1; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 619267-13-9; Drug: 619267-14-0; Drug: 619267-15-1; Drug: 619267-16-2; Drug: 619267-17-3; Drug: 619267-18-4; Drug: 619267-19-5; Drug: 619267-20-8; Drug: 619267-21-9; Drug: 619267-22-0; Drug: 619267-23-1; Drug: 619267-24-2; Drug: 619267-25-3; Drug: 619267-26-4; Drug: 678187-02-5; Drug: 678187-03-6; Drug: 678187-04-7; Drug: 678187-05-8; Drug: 678187-06-9; Drug: 678187-07-0; Drug: 678187-08-1; Drug: 678187-09-2; Drug: 678187-10-5; Drug: 678187-11-6; Drug: 678187-12-7; Drug: 678187-13-8; Drug: 678187-14-9. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 15027874
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 902779-03-7; Drug: 908843-57-2; Drug: 908843-58-3; Drug: 908843-61-8; Drug: 908843-63-0; Drug: 908843-68-5; Drug: 908843-70-9; Drug: 908843-73-2; Drug: 908843-74-3; Drug: 908843-75-4; Drug: 908843-76-5; Drug: 908843-77-6; Drug: 908843-78-7; Drug: 908843-79-8; Drug: 908843-80-1; Drug: 908843-81-2; Drug: 908843-82-3; Drug: 908843-84-5. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16675220
microtubule polymerization (GO:0046785) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 902779-03-7; Drug: 908843-57-2; Drug: 908843-58-3; Drug: 908843-61-8; Drug: 908843-63-0; Drug: 908843-68-5; Drug: 908843-70-9; Drug: 908843-73-2; Drug: 908843-74-3; Drug: 908843-75-4; Drug: 908843-76-5; Drug: 908843-77-6; Drug: 908843-78-7; Drug: 908843-79-8; Drug: 908843-80-1; Drug: 908843-81-2; Drug: 908843-82-3; Drug: 908843-84-5. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16675220
microtubule polymerization (GO:0046785) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania tarentolae 79195  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 483279-44-3; Drug: 619267-15-1. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16753146
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana 449723  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16918078
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania infantum 449723  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16918078
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 449723  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. References: 16918078

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Druggability index (range: 0 to 1): 0.5


Known modulators for this target

64 chemical compounds are associated with this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
Species Target Length Identity Alignment span Linked Drugs Reference
Bos taurus Tubulin 85 aa 28.2% 110 aa Compounds References
Bos taurus Tubulin beta chain 445 aa 30.9% 469 aa Compounds References
Ovis aries Tubulin alpha 4a 448 aa 27.9% 469 aa Compounds References
Rattus norvegicus Tubulin alpha-1 chain 451 aa 27.5% 469 aa Compounds References
Bos taurus Tubulin 445 aa 30.9% 469 aa Compounds References
Sus scrofa Tubulin alpha chain 451 aa 27.5% 469 aa Compounds References
Sus scrofa Tubulin 445 aa 30.3% 465 aa Compounds References

Obtained from network model

Ranking Plot


Putative Drugs List


Compound Raw Global Species
0.0294 0.4845 0.3816
0.038 0.3692 0.3689
0.2043 0.5382 0.5381
0.0137 0.5054 0.5054
0.0812 0.4723 0.4723
0.0289 0.3725 0.3725
0.0134 0.3347 0
0.0141 0.3392 0
0.0812 0.4723 0.4723
0.1405 0.5136 0.5045
0.1408 0.4595 0.5516
0.2048 0.4878 0.5381
0.0139 0.3392 0
0.0196 0.3729 0.3729
0.063 0.6104 0.6104
0.0263 0.3178 0.2732
0.0236 0.6661 0.5
0.2053 0.5373 0.5371
0.0431 0.3843 0.3309
0.1147 0.3352 0.5678
0.0134 0.3392 0
0.0966 0.2864 0.5651
0.0407 0.5054 0.5271
0.1813 0.552 0.552
0.0987 0.2669 0.5327
0.0139 0.4532 0.4008
0.0145 0.5091 0.3748
0.1069 0.2988 0.5479
0.0873 0.5375 0.5354
0.0258 0.3496 0.2724
0.0132 0.462 0.4008
0.0912 0.2829 0.5676
0.013 0.326 0.326
0.0179 0.3551 0.3551
0.0294 0.4845 0.3816
0.0182 0.4071 0.4035
0.0507 0.2651 0
0.044 0.5284 0.5262
0.031 0.3516 0.5935
0.0522 0.2879 0.4852
0.2094 0.5351 0.5351
0.0941 0.2835 0.5681
0.0344 0.3407 0.5303
0.0251 0.5402 0.5386
0.0261 0.2564 0.5375
0.0145 0.3392 0
0.0395 0.5316 0.5306
0.0116 0.3065 0.2648
0.0134 0.3392 0
0.007 0.2831 0
0.0798 0.4597 0.3418
0.0522 0.2879 0.4852
0.0505 0.5684 0.5681
0.013 0.5084 0.4008
0.0268 0.5259 0.4188
0.0258 0.3471 0.5248
0.0131 0.3392 0
0.006 0.2882 1
0.046 0.2733 0.4477
0.0941 0.6046 0.601
0.0145 0.3544 0
0.0929 0.2832 0.5678
0.2174 0.4299 0.5319
0.1366 0.5329 0.5325
0.0423 0.3287 0.527
0.0333 0.3437 0.5306
0.0798 0.4597 0.3418
0.0182 0.3842 0.2754
0.0298 0.4717 0.3673
0.0253 0.3918 0.3918
0.104 0.2872 0.563
0.1905 0.5369 0.5367
0.0522 0.2879 0.4852
0.0249 0.3749 0.3673
0.0318 0.5975 0.5946
0.0617 0.2524 0.5745
0.0491 0.5253 0.5252
0.0812 0.4723 0.4723
0.0636 0.6053 0.6053
0.0925 0.3824 0.5874
0.0207 0.3147 0.2745
0.1574 0.538 0.5377
0.2048 0.4878 0.5381
0.0352 0.4792 0.5997
0.0135 0.3392 0
0.2141 0.5326 0.5326
0.0549 0.448 0.446
0.0293 0.2733 0
0.0129 0.4008 0.4008
0.028 0.3145 0.3784
0.1055 0.5384 0.5384
0.0273 0.3209 0.5017
0.0559 0.5037 0.5037
0.2048 0.4878 0.5381
0.0181 0.3287 0.3583
0.0123 0.4335 0.4008
0.0127 0.3392 0
0.0136 0.3392 0
0.0307 0.3446 0.3731
0.0184 0.2597 0.5378
0.0136 0.3392 0
0.0362 0.3067 0.5295
0.0135 0.3392 0
0.0286 0.2721 0.2721
0.0134 0.253 0
0.0125 0.3392 0
0.1567 0.5381 0.5378
0.0929 0.2828 0.5677
0.0417 0.3295 0.5271
0.0993 0.5875 0.0798
0.0987 0.2813 0.5651

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.21.1010 (Leishmania major), epsilon tubulin, putative
Title for this comment
Comment